StratDeck

Two stocks in Healthcare

Genmab A/S vs Synektik Spółka Akcyjna: profit, growth, debt and price compared

Synektik Spółka Akcyjna is stronger on 4 of 6 figures: profit margin, sales growth, debt and price for its expected profit. Genmab A/S is stronger on 2: analysts' view and price trend.

Figures as of 20 November 2026Yahoo Finance
Explore Genmab A/S' storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Genmab A/S and Synektik Spółka Akcyjna side by side
Genmab A/SGMAB.COSynektik Spółka AkcyjnaSNT.WA
Net margin17.0%Stronger: 44.8%
Revenue growth, past year+16.10%Stronger: +89.50%
Debt to equity82.1%Stronger: 19.4%
Forward P/E29.6×Stronger: 25.9×
Dividend yield—3.40%
AnalystsStronger: Strong buy · 13Buy · 5
From its 200-day averageStronger: +52.0%−3.1%

Share price over the past year

  • Genmab A/S+75.3%
  • Synektik Spółka Akcyjna+20.8%

19 Nov 202520 Nov 2026

Genmab A/S or Synektik Spółka Akcyjna: which is stronger?

  • SNT.WA

    Which is more profitable?

    Synektik Spółka Akcyjna keeps more of each sale as profit: 44.8% against 17.0%.

  • SNT.WA

    Which is growing its sales faster?

    Synektik Spółka Akcyjna is growing its sales faster: +89.50% over the past year, against +16.10%.

  • SNT.WA

    Which has borrowed less?

    Synektik Spółka Akcyjna has borrowed less: its debt is 19.4% of what its shareholders own, against 82.1% for Genmab A/S.

  • SNT.WA

    Which costs less for the profit it is expected to make?

    Synektik Spółka Akcyjna costs less for the profit it is expected to make: 25.9× its forward earnings, against 29.6×.

  • Which pays more in dividends?

    Synektik Spółka Akcyjna pays 3.40% a year in dividends for what a share costs, where Genmab A/S pays none.

  • GMAB.CO

    Which do analysts rate higher?

    Analysts are warmer on Genmab A/S: Strong buy, against Buy for Synektik Spółka Akcyjna.

  • GMAB.CO

    Which is in the stronger price trend?

    Genmab A/S' price is in the stronger trend: 52.0% above its 200-day average, against 3.1% below.

What each company does

GMAB.COGenmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.

Reports results on 16 February 2027

SNT.WASynektik Spółka Akcyjna

Synektik Spółka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland.

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.